Oppenheimer Downgrades INSYS Therapeutics (INSY) to Perform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Insys Therapeutics (INSY) Tops Q3 EPS by 34c
November 11, 2014 6:51 AM ESTInsys Therapeutics (NASDAQ: INSY) reported Q3 EPS of $0.63, $0.34 better than the analyst estimate of $0.29. Revenue for the quarter came in at $58.3 million versus the consensus estimate of $57.1 million.
Subsequent Events Pipeline Developments
Insys... More